Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Anavex Life Sciences ( NASDAQ:AVXL ) , POET Technologies ( NASDAQ:POET )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday. Shares of Red Cat Holdings Inc ( NASDAQ:RCAT ) fell sharply in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY25 sales guidance ...
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
Company plans to request re-examination after CHMP opinion feedback following its oral explanation ...
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease - Anavex Life Sciences ( NASDAQ:AVXL )
Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results
Why Is Anavex Life Sciences Stock Trading Higher Today? - Anavex Life Sciences ( NASDAQ:AVXL )
On Wednesday, Anavex Life Sciences Corp. ( NASDAQ:AVXL ) announced new findings for blarcamesine, an oral small molecule for early Alzheimer's disease. New data demonstrate continued long-term benefit from oral blarcamesine compared to the decline observed in the Alzheimer's Disease ...
Why Is Anavex Life Sciences Stock Trading Higher Today? - Anavex Life Sciences ( NASDAQ:AVXL )
On Wednesday, Anavex Life Sciences Corp. ( NASDAQ:AVXL ) announced new findings for blarcamesine, an oral small molecule for early Alzheimer's disease. New data demonstrate continued long-term benefit from oral blarcamesine compared to the decline observed in the Alzheimer's Disease ...
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative ( ADNI ) Control Group
ADAS-Cog13 difference −12.78 ( P < 0.0001 ) with oral blarcamesine treatment compared to ADNI control group at Week ...
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care'
Presentation title: "Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine" Presentation title: "Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral ...
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults ...
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia ...
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer's disease ...
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
NEW YORK, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) ( Nasdaq: AVXL ) , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, ...
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows - Anavex Life Sciences ( NASDAQ:AVXL )
Pre-treatment with blarcamesine prevented memory impairment in Alzheimer's mouse model. SIGMAR1 activation linked to reduced oxidative stress and restored cellular balance. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. Anavex Life Sciences Corp.
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease
Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline ...
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time ...
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 - Anavex Life Sciences ( NASDAQ:AVXL )
NEW YORK, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) AVXL, a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, ...
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
Webcast and Conference Call To be Held Tuesday, August 12, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 12, 2025, 8:30 am ET ...
Anavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months - Anavex Life Sciences ( NASDAQ:AVXL )
Early blarcamesine use showed significant cognitive and functional benefits at 192 weeks. ABCLEAR1 subgroup saw up to 49.8% improvement in cognition and 35.5% in function. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. Anavex Life Sciences Corp.
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
New clinical Precision Medicine population data demonstrates up to 84.6 Weeks ( 19.5 Months ) 'time saved' by ...
Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences ( AVXL ) is a Great Choice
Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Adaptive Biotechnologies ( ADPT ) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. ( NASDAQ: AVXL ) and Encourages Long-Term Investors to Contact the Firm - Anavex Life Sciences ( NASDAQ:AVXL )
PHILADELPHIA, June 16, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Anavex Life Sciences Corp. AVXL ( "Anavex" ) on behalf of the company's long-term shareholders.
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions - Aardvark Therapeutics ( NASDAQ:AARD )
Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
SAN DIEGO, May 19, 2025 ( GLOBE NEWSWIRE ) -- Aardvark Therapeutics, Inc. ( Aardvark ) ( Nasdaq: AARD ) , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today ...
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference ...
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time ...
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 - Anavex Life Sciences ( NASDAQ:AVXL )
NEW YORK, May 06, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) AVXL, a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, ...
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - Anavex Life Sciences ( NASDAQ:AVXL )
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A ( 16 participants ) and Part B ( 55 participants ) of the placebo-controlled Phase 2 study fully enrolled Top line data expected in the second half of 2025
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants ...
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
NEW YORK, April 30, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) ( Nasdaq: AVXL ) , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, ...
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board - Anavex Life Sciences ( NASDAQ:AVXL )
NEW YORK, April 23, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) AVXL, a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, ...
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East - Anavex Life Sciences ( NASDAQ:AVXL )
NEW YORK, April 21, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) AVXL, a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, ...
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East
NEW YORK, April 21, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) ( Nasdaq: AVXL ) , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, ...
Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years - Anavex Life Sciences ( NASDAQ:AVXL )
Blarcamesine cut cognitive decline by 3.83 points on ADAS-Cog13 vs. delayed start at Week 192 ( P = 0.0165 ) Functional ability improved by 5.75 points on ADCS-ADL with early, consistent blarcamesine use ( P = 0.0015 ) With stocks plunging, steady income is key.
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference ...
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference - Anavex Life Sciences ( NASDAQ:AVXL )
NEW YORK, March 31, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) AVXL, a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, ...
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
NEW YORK, March 31, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) ( Nasdaq: AVXL ) , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, ...
Beat the Market the Zacks Way: Amgen, DRDGOLD, Anavex in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
NEW YORK, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) ( Nasdaq: AVXL ) , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, ...
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday? - American Intl Gr ( NYSE:AIG )
A hotter-than-expected inflation report initially rattled markets, but stocks rebounded as investors bought the dip. Treasury yields surged as traders reduced rate cut expectations, pushing the 10-year yield to 4.64%.
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 - Anavex Life Sciences ( NASDAQ:AVXL )
NEW YORK, Feb. 05, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) AVXL, a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, ...
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET ...
Anavex Life Sciences Announces Issuance of Blarcamesine ( ANAVEX®2-73 ) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio - Anavex Life Sciences ( NASDAQ:AVXL )
NEW YORK, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) AVXL, a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, ...
Anavex Life Sciences Announces Issuance of Blarcamesine ( ANAVEX®2-73 ) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent for Alzheimer's Disease ...
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.
Best Momentum Stocks to Buy for January 21st
CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.
New Strong Buy Stocks for January 21st
CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025.
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients - Anavex Life Sciences ( NASDAQ:AVXL )
Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Blarcamesine exhibited a favorable safety profile with no treatment-related deaths
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients
Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years ...
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( "Anavex" or the "Company" ) ( Nasdaq: AVXL ) , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, ...
Are Medical Stocks Lagging Anavex Life Sciences ( AVXL ) This Year?
Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.
